Skip to main content

Low-Concentration Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT2 Randomized Clinical Trial

In brief

In children with myopia and eye misalignment, 0.04% atropine slowed progression most

In a randomized trial, children using 0.04% atropine had 0.18 diopters of myopia progression over 12 months, compared with 0.35 and 0.43 diopters with 0.02% and 0.01% drops; their eyes also elongated less. Light sensitivity was more common with 0.04% drops, affecting about 1 in 5 children, and the possible improvement in eye alignment needs further study.

Journal
JAMA ophthalmology (Q1)
Published
19 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Zijin Wang, Xiaoxia Zuo, Hanyang Tang, Yuting Zhang, Tianxi Li, Yunhan Xie, et al.
PMID
43056108
DOI
10.1001/jamaophthalmol.2026.5250

Why clinicians should know about it

  • Picked for Ophthalmology (top studies of the week, 22 November 2026): Randomized trial of atropine for childhood myopia and exotropia

Abstract

IMPORTANCE: The optimal atropine concentration for myopia control in children with coexisting intermittent exotropia (IXT) remains uncertain. OBJECTIVE: To compare the efficacy and safety of 0.01%, 0.02%, and 0.04% atropine eye drops in children with myopia and IXT. DESIGN, SETTING, AND PARTICIPANTS: This single-center, double-masked, 3-arm randomized clinical trial was conducted from September 2023 to March 2026. Children aged 6 to 12 years with basic-type IXT and myopia (cycloplegic spherical equivalent [SE], -0.50 to -6.00 diopters [D]) were enrolled. Data analysis was conducted from March 2026 to July 2026. INTERVENTIONS: Participants were randomized 1:1:1 to 0.01%, 0.02%, or 0.04% atropine eye drops nightly in both eyes. MAIN OUTCOMES AND MEASURES: The primary outcome was 12-month change in cycloplegic SE. Secondary outcomes included changes in axial length (AL), exotropia conditions, binocular vision, and ocular safety parameters. RESULTS: Among 264 randomized children (mean [SD] age, 8.4 [1.5] years; 130 female [49.2%]), 224 (84.8%) completed the 12-month assessment. Mean (SD) SE changes were -0.43 (0.50) D, -0.35 (0.51) D, and -0.18 (0.60) D with 0.01%, 0.02%, and 0.04% atropine, respectively (overall P = .001). Compared with 0.01% and 0.02% atropine, 0.04% atropine was associated with less SE progression (vs 0.01%: difference, 0.24 D; 95% CI, 0.11-0.37 D; P < .001; vs 0.02%: difference, 0.16 D; 95% CI, 0.04-0.29 D; P = .02). Mean (SD) AL changes were 0.31 (0.25) mm, 0.25 (0.23) mm, and 0.15 (0.29) mm, respectively (overall P < .001); corresponding differences for 0.04% vs 0.01% and 0.02% were -0.16 mm (95% CI, -0.22 to -0.10 mm; P < .001) and -0.10 mm (95% CI, -0.16 to -0.04 mm; P < .001). Mean (SD) near exodeviation decreased by 3.46 (5.76) prism diopters (PD), 4.84 (8.05) PD, and 6.13 (7.11) PD, respectively (overall P = .04); the reduction was greater with 0.04% vs 0.01% atropine (difference, -2.68 PD; 95% CI, -4.78 to -0.57 PD; P = .008). Study drug-related photophobia occurred in 8 (9.1%), 9 (10.2%), and 19 participants (21.6%) in the 0.01%, 0.02%, and 0.04% atropine groups, respectively; no participant discontinued treatment because of photophobia. CONCLUSIONS AND RELEVANCE: In the AMIXT2 randomized clinical trial among children with myopia and IXT, 0.04% atropine eye drops were associated with less myopia progression and axial elongation over 12 months than 0.01% or 0.02% atropine eye drops. Higher concentrations were associated with greater reductions in near magnitude of exodeviation, which warrant further investigation. TRIAL REGISTRATION: chictr.org.cn Identifier: ChiCTR2300075312.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.